Calliditas Therapeutics AB (CALTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
25
About the Report
About the Report
Summary
Calliditas Therapeutics AB (Calliditas Therapeutics), formerly Pharmalink AB is a pharmaceutical company that develops, identifies, and commercializes pharmaceutical products for niche indications. The company's pipeline products include Busulipo that is under Phase II clinical trials and Nefecon for IgA Nephritis that is under Phase II clinical trials. Its pipeline product also comprises Xepol XP-28 that is used for the treatment of post-polio syndrome and is under pre-license sales. Calliditas Therapeutics also partners with medical research institutions such as the Karolinska Institute and Uppsala University. The company offers its products and services across Sweden. Calliditas Therapeutics is headquartered in Stockholm, Sweden.
Calliditas Therapeutics AB (CALTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Pharmalink Acquires Anti-Inflammatory Drug from Synartro 10
Venture Financing 11
Pharmalink Raises USD12 Million in Financing 11
Pharmalink Raises USD 15 Million In Series C Financing 12
Pharmalink Secures USD 5.1 Million In Series B Financing 14
Equity Offering 15
Calliditas Therapeutics Prices IPO for USD75 Million 15
Pharmalink Plans IPO 16
Calliditas Therapeutics AB-Key Competitors 17
Calliditas Therapeutics AB-Key Employees 18
Calliditas Therapeutics AB-Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Jun 29, 2018: Nasdaq Stockholm Welcomes Calliditas Therapeutics to the Main Market 20
Aug 24, 2017: Thomas Eklund New Chairman of Pharmalink 21
Aug 15, 2017: Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications 22
Jan 09, 2017: Pharmalink strengthens board with appointment of Maria Carell as Chair 23
Other Significant Developments 24
Nov 15, 2017: Pharmalink is renamed Calliditas Therapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25
List of Figure
List of Figures
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calliditas Therapeutics AB, Deals By Therapy Area, 2012 to YTD 2018 8
Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharmalink Acquires Anti-Inflammatory Drug from Synartro 10
Pharmalink Raises USD12 Million in Financing 11
Pharmalink Raises USD 15 Million In Series C Financing 12
Pharmalink Secures USD 5.1 Million In Series B Financing 14
Calliditas Therapeutics Prices IPO for USD75 Million 15
Pharmalink Plans IPO 16
Calliditas Therapeutics AB, Key Competitors 17
Calliditas Therapeutics AB, Key Employees 18
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.